𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vindesine: A phase II study in childhood malignancies-A report for cancer and leukemia group B

✍ Scribed by Ettinger, Lawrence J. ;Brecher, Martin ;Coleman, Morton ;Smithson, W. Anthony ;Patterson, Richard ;Russell, E. Clifton ;Necheles, Thomas ;Jones, Barbara ;Ohnuma, Takao

Publisher
John Wiley and Sons
Year
1982
Tongue
English
Weight
538 KB
Volume
10
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Vindesine, a semisynthetic derivative of vinblastine sulfate, was tested for anti‐tumor activity and clinical toxicity in 36 children. The drug was administered to the initial 13 patients entered into the study a 2 mg/m^2^/day for five days by IV bolus. Because of severe neurotoxicity and life‐threatening gastrointestinal toxicity, the regimen in 23 patients was modified to 4 mg/m^2^ IV infusion over four hours, weekly. This latter regimen was well tolerated, with acceptable gastrointestinal, hematological, and neurotoxicity. One child with acute lymphocytic leukemia resistant to vincristine had a transient Ml remission bone marrow. Improvement or stable disease was noted in one patient each with Ewing's sarcoma, neuroblastoma, and Hodgkin's disease.

πŸ“œ SIMILAR VOLUMES

Phase I/II study of bisantrene in childh
Phase I/II study of bisantrene in childhood cancer: A report from the childrens cancer study group
✍ Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 328 KB

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect

Phase II trial of cis-dichlorodiamminepl
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
✍ F. Cavalli; Dr. W. F. Jungi; N. I. Nissen; T. F. Pajak; M. Coleman; J. F. Hollan πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 279 KB πŸ‘ 3 views

In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(l1) (cis-platinum) once every three weeks. All patients had received extensive prior therapy. Partial remission was obtai